Drug Profile
Research programme: opioid abuse therapeutics - Axim Biotech
Alternative Names: Opioid antagonists plus cannabinoids - Axim BiotechLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Axim Biotech
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Opioid-related disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Opioid-related-disorders(Combination therapy) in USA
- 15 Aug 2017 Early research in Opioid abuse (Combination therapy) in USA (unspecified route)
- 23 Jun 2017 Axim Biotech files for patent protection for opioid abuse therapeutics